India has numerous pharmaceutical companies, each impacting thousands of lives globally with healthcare solutions. Granules India stands out as one of India’s largest pharmaceutical companies.
What makes this company unique?
They focus on healing lives through innovative green science.
Interested in learning more about a company that’s been serving India for over four decades?
Let’s explore the history of Granules India today!
History of Granules India Limited: From Hyderabad to Serving 80 Countries Worldwide
Krishna Prasad Chigurupati is the man behind Granules India.
The company was founded in 1984 as Triton Laboratories. Triton produced Paracetamol API at its Bonthapally factory on the outskirts of Hyderabad.
However, scientists discovered a more efficient way to produce the Paracetamol API.
This marked the beginning of Granules’ growth!
In 1987, Triton became the second Indian company, after Dr Reddy’s Laboratories, to export pharmaceutical products to the U.S.
Let’s take a trip down memory lane to see how Granules India Ltd started!
In 1984, Triton Laboratories took its first steps in Hyderabad!
Their mission began with the production of Paracetamol API at their Bonthapally facility.
It marked the beginning of something significant.
By 1990, they doubled down with a second facility at Jeedimetla for multiple APIs.
Triton was expanding its horizons.
In 1991, Granules India Private Limited entered the arena, further expanding with their first PFI facility at Jeedimetla in 1993.
Listed on the Hyderabad Stock Exchange in 1995, they made waves in the industry.
The merger of Triton with Granules in 2001 joined forces for growth.
2003 – Innovation was at the heart of Granules’ strategy.
They expanded with a new, state-of-the-art PFI facility in Gagillapur.
Were they done?
Nah!
They launched Granules USA to conquer the American market.
Back in Bonthapally, Triton Laboratories celebrated a new milestone with the inauguration of a modern Paracetamol plant in 2005!
2008 – Granules ventured into the Finished Dosage segment, diversifying its portfolio.
The pinnacle of success came when Granules received its first US FDA approval for an Abbreviated New Drug Application (ANDA) in 2010.
It validated their commitment to quality and regulatory compliance.
2013 – Never one to rest on their laurels, Granules established an API R&D facility in Pragathi Nagar, Hyderabad.
It became a hub of innovation, driving their quest for cutting-edge pharmaceutical solutions.
By 2014, acquisitions were on the agenda. Granules acquired Auctus Pharma, expanding their manufacturing capabilities and regulatory approvals. Meanwhile, they set up Granules Pharmaceuticals in the US, focusing on formulation R&D.
Granules took a bold step into the US Over-the-Counter market with their own label, Granules Consumer Healthcare. This strategic move in 2015 aimed to control the value chain and enhance their market presence.
In 2016 – The future was taking shape with the foundation laid for an Oncology OSD Plant in Visakhapatnam.
2017 – Granules launched the Self Directed Team (SDT) program. It was about nurturing talent and building a strong organizational culture.
2018 – Continuous improvement became ingrained in Granules’ DNA with the initiation of the LEAN SIX-Sigma Program. They aimed to streamline operations and achieve operational excellence across all business areas.
Crossing another milestone in 2019, Granules joined the front-end business for the sale of Rx Products in the US under the GPI Label.
It was a strategic move to expand their market reach!
2020 – The groundwork was laid for the largest single manufacturing site for the Multi-Unit Pellet system facility.
2023 – Looking to the future, Granules inaugurated GPAK. This is a cutting-edge packaging facility with four suites and a warehouse.
Today, Granules India Limited continues to innovate its products and business.
Its massive facilities can handle large batches, meeting global demand efficiently. But it’s not just about quantity; the company has a strong research and development team. They continuously seek ways to improve products and processes!
Now, Granules India is even distributing its own labelled products across various global markets, marking a new chapter in its story.
About Granules India Limited | An Overview
Imagine a company that has quietly yet powerfully influenced the pharmaceutical world for nearly four decades.
Granules India, headquartered in Hyderabad, seamlessly blends science with innovation.
Their aim?
To ensure excellence in high-quality medicine production!
Granules India offers high-quality APIs, FD, PFI, and speciality products with a strong customer-centric focus.
As a global player, Granules India has grown significantly due to its vertically integrated model. This helps the company to control every step of production.
Core Values:
- Challenging limits
- Futuristic thinking
- Customer-centricity
- Empowering employees
- Maintaining quality
- Environmental stewardship
From state-of-the-art facilities in India to a formulation R&D center in Virginia, USA, Granules India is on a mission to responsibly improve lives.
This is the Granules way.
Granules India Products:
- Active Pharmaceutical Ingredients
- Pharmaceutical Formulations Intermediates
- Finished Dosages
- High Potent Products
Granules India Owner: Dr. Krishna Prasad Chigurupati
Granules India Chairman/Joint Managing Director: Dr. Krishna Prasad Chigurupati
Granules India Global Presence: Over 300 customers in 80+ Countries
Granules India Regulatory Approvals: 87
Granules India Turnover Revenue (Cr.), FY24: ₹4,5064
Granules India Number of Employees: 4,000+
Granules India Number of Products: 60+
Granules India Market Cap (as of July 26th, 2024): ₹12,555 Cr.
Granules India Share Price (Current Price): ₹557
Building a Brighter Future Through Sustainable Growth
Granules India aims to be one of the most sustainable companies. This year, they have taken significant steps to enhance their sustainability journey and prepare for the future.
Sustainability is at the heart of Granules’ vision!
It guides their choices and actions, ensuring they prioritize long-term environmental and social considerations alongside business objectives.
Their product development process includes initiatives like the Green Card and Eco Scale.
FAQs| Granules India Limited
Granules India is known for its strong market presence and positive employee reviews.
Granules India manufactures various pharmaceutical products such as APIs, PFIs and finished dosages (FDs). Some of the FDs include Paracetamol, Ibuprofen, and Metformin.
Granules India was co-founded by Krishna Prasad Chigurupati, who serves as the Chairman and Managing Director.
Yes, Granules India is an Indian multinational pharmaceutical company with a global presence.
As of July 2024, the share price of Granules India is approximately ₹557.
No, Granules India is a publicly traded company and not owned or operated by the government.
______________________________________________________________________________________
Disclaimer: Investments in the securities market are subject to market risks; read all the related documents carefully before investing.